Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GOBLET trial
2024-512275-12-00Phase 4Completed
- Sponsor
- Rigshospitalet
- Start
- Mar 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of latanoprost in ocular hypertension and open-angle glaucoma (OAG) (2 arms), sponsored by Rigshospitalet. Primary endpoint: change in goblet cell density. Started Mar 2024; status: completed.
02
Drugs
latanoprost
03
Conditions
ocular hypertensionopen-angle glaucoma (OAG)
Beyond the preview
Go deeper on 2024-512275-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512275-12-00.